• Shopping Cart Shopping Cart
    0Shopping Cart
XL-protein offers PASylation, a biological alternative to PEGylation
  • About
    • Corporate overview
    • Leadership team
  • Technology
    • Overview
    • Applications
      • Eye diseases
      • Cytokines
      • Enzymes
      • Peptides
      • Antibody fragments
      • Nanoparticles
      • In vivo imaging
      • AnimalHealth
    • PAS-Advantages
    • Intellectual property
  • Partnering
    • Partnering
  • News & Publications
    • Press Releases
    • Receive our Press Releases
    • Partner’s Press Releases
    • Key publications
    • Various publications
  • Careers
  • Contact
    • Contact
    • Imprint
    • Disclaimer
  • PAS-Shop
    • Products
    • Terms & Conditions
    • Privacy Policy
    • Shipping
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

10. June 2025
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362025-06-10 11:00:002025-06-10 11:20:12XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

15. February 2023
NEW YORK and LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) — Akari…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362023-02-15 10:04:522023-02-21 10:07:28Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Bavarian Research Foundation supports the development of an immunosuppressive PASylated antibody fragment to support cardiac xenotransplantation

28. September 2022
Munich, September 28, 2022 – A research consortium composed…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362022-09-28 15:10:002022-09-28 15:54:56Bavarian Research Foundation supports the development of an immunosuppressive PASylated antibody fragment to support cardiac xenotransplantation
Page 1 of 11123›»
© 2024 - All Rights Reserved for XL-protein GmbH | Imprint | Disclaimer | Data Privacy Policy | Terms & Conditions
  • Link to Mail
Scroll to top Scroll to top Scroll to top